Product Description
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Gene Therapy
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Jennerex Biotherapeutics
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: France
Active Clinical Trial Count: 1
Highest Development Phases
Phase 1: Liver Cancer|Pregnancy Outcomes|Vaccinia
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| ISI-JX | P1 |
Completed |
Pregnancy Outcomes|Liver Cancer|Vaccinia |
2022-04-13 |
21% |